Synchronous triple primary malignant tumours in the bladder, prostate, and lung harbouring TP53 and MEK1 mutations accompanied with severe cardiovascular diseases: A case report
Although the incidence of multiple primary malignancies (MPMs) is increasing, synchronous triple primary malignant tumours with prostate, bladder and lung is rarely reported. Gene mutation is thought to be a reason for MPMs, and severe cardiovascular diseases may interrupt the cancer treatment. Here...
Main Authors: | Li Zhi-Ke, Zhao Qiang, Li Ning-Fu, Wen Jing, Tan Bang-Xian, Ma Dai-Yuan, Du Guo-Bo |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2022-12-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2022-0616 |
Similar Items
-
The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
by: Shuhang Wang, et al.
Published: (2022-01-01) -
<i>TP53</i> Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia
by: Heba Alkhatabi, et al.
Published: (2022-03-01) -
Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer
by: YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei
Published: (2022-09-01) -
<i>TP53</i> Abnormalities and MMR Preservation in 5 Cases of Proliferating Trichilemmal Tumours
by: Raquel Martín-Sanz, et al.
Published: (2021-05-01) -
Systematic evaluation of TP53 codon 72 polymorphism associated with onset and progression of oral potentially malignant disorders
by: Huangkai Li, et al.
Published: (2023-09-01)